A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Por um escritor misterioso
Descrição
Mean (A) ASDAS and (B) BASDAI up to Week 48. Safety Set (N=89).
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
Axial spondyloarthritis - The Lancet
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
Physical activity in ankylosing spondylitis: evaluation and analysis of an eHealth tool
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study - Irene E. van der Horst-Bruinsma, Rianne E.
A) ASAS20, ASAS40 and ASAS partial remission responder rates up to
WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents
New evidence on the management of spondyloarthritis
Recommendations for the management and treatment of ankylosing spondylitis – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
New evidence on the management of spondyloarthritis
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. - Abstract - Europe PMC
de
por adulto (o preço varia de acordo com o tamanho do grupo)